ESMO Gastrointestinal Oncology最新文献

{"title":"Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study","authors":"A. Sartore-Bianchi ,&nbsp;F. Toscano ,&nbsp;D.P. Bernasconi ,&nbsp;A. Curaba ,&nbsp;P. Colombo ,&nbsp;C. Mazzali ,&nbsp;A. Piantelli ,&nbsp;A. Dotti ,&nbsp;D. Tedesco ,&nbsp;K. Bencardino ,&nbsp;A. Amatu ,&nbsp;F. Tosi ,&nbsp;E. Bonazzina ,&nbsp;F. Villa ,&nbsp;V. Gori ,&nbsp;D. Piscazzi ,&nbsp;A.G. Agostara ,&nbsp;G. Calvanese ,&nbsp;G. Saporetti ,&nbsp;S. Siena","doi":"10.1016/j.esmogo.2025.100224","DOIUrl":"10.1016/j.esmogo.2025.100224","url":null,"abstract":"<div><h3>Background</h3><div>Patient-reported experience measures (PREMs) offer an objective measure of the patient experience by investigating various fields of the care pathway. We analyzed PREMs in patients with metastatic colorectal cancer (mCRC) undergoing anticancer therapy integrating an auditing process to allow corrective actions.</div></div><div><h3>Materials and methods</h3><div>This is a prospective, observational, monocentric study with a four-phase sequential design: phase I validation of the PREMs questionnaires in five-level Likert item format in Italian; phase II administration of questionnaires at T0 (0-30 days since the start of oncology care), T1 (30 days-6 months), T2 (6-12 months), T3 (&gt;12 months); phase III analysis of results during quality audits and implementation of strategies to improve care pathways; phase IV re-administration and results compared with phase II.</div></div><div><h3>Results</h3><div>PREMs were tested for validity in 47 patients (phase I of the EPIC study). In phase II, 102 patients were enrolled, 150 questionnaires were administered and 142 returned (94.6%). Sixteen questions grouped in four areas (information about care path, contacts and accessibility, patient needs, health care awareness monitoring) were analyzed. A high proportion of patients were concerned about their future/possibility of relapse at T1 (61.6%/58.3%) and T2 (62.5%/63.7%). After the implementation of a checklist for clinicians (phase III), in phase IV, 74 patients were enrolled and the proportion of patients concerned about their future/possibility of a relapse decreased at T1 (35.7%/25%) and T2 (31.3%/43.4%).</div></div><div><h3>Conclusions</h3><div>PREMs evaluation is feasible in the setting of mCRC. A checklist for clinicians tailored after an <em>ad hoc</em> audit improved results about patients’ concerns about their future and possibility of relapse.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of tumor-associated microbiome in multifocal small intestinal neuroendocrine tumors (SI-NETs)","authors":"I.T. Lee ,&nbsp;A. Dohlman ,&nbsp;T. Gao ,&nbsp;Z. Zhang ,&nbsp;Y. Kasai ,&nbsp;G.E. Kim ,&nbsp;C. Thirlwell ,&nbsp;E. Nakakura ,&nbsp;M. Meyerson ,&nbsp;N. Mäkinen","doi":"10.1016/j.esmogo.2025.100229","DOIUrl":"10.1016/j.esmogo.2025.100229","url":null,"abstract":"<div><h3>Background</h3><div>Small intestinal neuroendocrine tumors (SI-NETs) are among the most common neoplasms of the small bowel; however, the molecular mechanisms underlying their pathogenesis are largely unknown. The multifocal nature of SI-NETs, their putative distinct genomic origins, and their enrichment in the distal ileum led us to hypothesize that environmental factors, such as pathogenic organisms, might play a role in the development of these lesions.</div></div><div><h3>Materials and methods</h3><div>To study the tumor-associated microbiome of multifocal SI-NETs and its potential role in pathogenesis, we used matched whole genome and transcriptome sequencing data from a cohort of 10 multifocal SI-NET patients, including 70 primary ileal NETs and their matched normal ileal mucosa and/or whole blood specimens.</div></div><div><h3>Results</h3><div>Microbial communities in the ileal tissue samples were primarily composed of bacteria. The most abundant genera included well-known gastrointestinal, oral, and mucosal bacteria. Ileal tissue samples from individual patients contained distinct patient-specific microbial communities. Although the microbiota composition did not show significant differences between ileal NET and normal ileal tissues, genus <em>Propionibacterium</em> was found to be enriched in the normal tissue specimens.</div></div><div><h3>Conclusions</h3><div>This study comprehensively characterizes the tissue-resident ileal microbiome of multifocal SI-NET patients. We provide clear evidence that the microbial communities in the ileum are largely patient specific, whereas our genus-level analyses suggest that SI-NET pathogenesis is unlikely driven by individual microorganisms present in the tumors at the time of surgical resection.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100229"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients","authors":"F. Salvà ,&nbsp;G. Catani ,&nbsp;N. Saoudi ,&nbsp;I. Baraibar ,&nbsp;J. Ros ,&nbsp;M. Rodriguez ,&nbsp;C. Salvà de Torres ,&nbsp;A. Alcaraz ,&nbsp;A. Garcia ,&nbsp;R. Comas ,&nbsp;F. Ruiz-Pace ,&nbsp;A. Rezqallah ,&nbsp;R. Dienstmann ,&nbsp;J. Tabernero ,&nbsp;E. Elez","doi":"10.1016/j.esmogo.2025.100230","DOIUrl":"10.1016/j.esmogo.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>Oxaliplatin, a key agent used for managing metastatic colorectal cancer (mCRC), is often discontinued due to cumulative toxicity. Its reintroduction in later treatment lines remains a common clinical practice, despite the absence of robust prospective trials supporting this therapeutic strategy. This study aimed to evaluate the efficacy of oxaliplatin rechallenge in refractory mCRC and to identify patient characteristics predictive of improved outcomes with this approach.</div></div><div><h3>Patients and methods</h3><div>We retrospectively analyzed patients treated with oxaliplatin in the third- or fourth-line setting at Vall d’Hebron Hospital between 2015 and 2021. Outcomes included overall response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS). Patients achieving median PFS &gt;6 months were classified as best-responders. Factors affecting PFS were analyzed with a Cox regression model. Amplicon-seq analysis of 61 genes was carried out using Illumina technology.</div></div><div><h3>Results</h3><div>Of 735 patients receiving third- or fourth-line treatment, 102 (14%) received oxaliplatin retreatment (69% in third line; 31% in fourth line). Median PFS was 4.0 months (95% CI 3.29-5.03 months), with an ORR of 12% and DCR of 39%. Twenty-eight patients (27%) were best-responders. Predictors of efficacy included response to first-line oxaliplatin, planned oxaliplatin discontinuation, and an oxaliplatin-free interval of at least 22.0 months. No significant associations were identified between molecular alterations and prognostic subgroups.</div></div><div><h3>Conclusions</h3><div>Oxaliplatin-based reintroduction therapy is a viable strategy in mCRC, particularly for patients with a favorable prior response and prolonged oxaliplatin-free intervals. However, identifying more precise biomarkers is essential to improve patient selection and maximize treatment efficacy.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations","authors":"J. Ros ,&nbsp;V. Navarro ,&nbsp;G. Villacampa ,&nbsp;I. Baraibar ,&nbsp;F. Salvà ,&nbsp;M. Rodriguez ,&nbsp;C. Vaghi ,&nbsp;A. Garcia ,&nbsp;A. Alcaraz ,&nbsp;J. Tabernero ,&nbsp;E. Élez ,&nbsp;R. Dienstmann","doi":"10.1016/j.esmogo.2025.100225","DOIUrl":"10.1016/j.esmogo.2025.100225","url":null,"abstract":"<div><h3>Background</h3><div>The <em>BRAF</em> V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with <em>BRAF</em> V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with <em>BRAF</em> V600E-mutant colorectal cancer treated with either BRAF inhibitor combinations or chemotherapy.</div></div><div><h3>Materials and methods</h3><div>A systematic review was carried out to identify clinical trials or real-world cohorts evaluating patients with <em>BRAF</em>-mutant colorectal cancer treated either with chemotherapy or BRAF inhibitor combinations. A control cohort of melanoma patients treated with BRAF inhibitors in a phase III randomized trial was included. Adjusted <em>R</em>² (<em>R</em>²_adj) values were calculated to quantify the association between surrogate endpoints and median OS.</div></div><div><h3>Results</h3><div>Overall, a total of 5227 patients included in 29 cohorts were analyzed. Among patients with colorectal cancer treated with chemotherapy, overall response rate (ORR) and disease control rate (DCR) showed a high correlation with OS (<em>R</em>²_adj &gt; 0.90). Among patients treated with targeted therapy, progression-free survival (PFS) showed the highest correlation with OS (<em>R</em>²_adj = 0.90). In the melanoma cohort, PFS was strongly associated with OS (<em>R</em>²_adj = 0.92).</div></div><div><h3>Conclusions</h3><div>In <em>BRAF</em>-mutant colorectal cancer, standard surrogate endpoints for chemotherapy-based treatments accurately predict OS; however, when patients are treated with targeted therapies, both ORR and PFS have proven to be reliable predictors of survival.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy","authors":"K. Sugiyama ,&nbsp;S. Kumar ,&nbsp;A. Chaudry ,&nbsp;N. Patel ,&nbsp;P. Patel ,&nbsp;D. Cunningham ,&nbsp;N. Starling ,&nbsp;S. Rao ,&nbsp;C. Fribbens ,&nbsp;L. Eldridge ,&nbsp;I. Chau","doi":"10.1016/j.esmogo.2025.100223","DOIUrl":"10.1016/j.esmogo.2025.100223","url":null,"abstract":"<div><h3>Background</h3><div>Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and nutritional status in patients with LA-OGA undergoing perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) treatment.</div></div><div><h3>Materials and methods</h3><div>We screened patients with LA-OGA (cT2-4 and/or N1-3) treated with FLOT from 423 patients who underwent radical resection at The Royal Marsden Hospital between 2017 and 2023. Nutritional status was assessed using body weight and prognostic nutritional index (PNI). The primary outcome was 3-year recurrence-free survival (RFS) rate. Survival time was estimated using Kaplan–Meier curves and restricted mean survival time at 36 months. Multivariate analyses were carried out. Pathological response was defined as a tumour regression grade of 1-2 using the Mandard criteria.</div></div><div><h3>Results</h3><div>A total of 210 patients met the inclusion criteria [median follow-up time, 26.5 months; 3-year RFS rate, 53% (95% confidence interval 45% to 60%)]. Weight loss and PNI at diagnosis and after neoadjuvant chemotherapy were not significant predictors of RFS. A decrease in PNI during neoadjuvant chemotherapy was associated with a significantly shorter 3-year RFS rate than a maintained or increased PNI (46% versus 69%, <em>P</em> &lt; 0.01). The restricted mean survival time difference was 5.46 months (95% confidence interval 1.73-9.19 months, <em>P</em> &lt; 0.001). A decreased PNI (<em>P</em> = 0.03) independently and negatively predicted RFS. The pathological response was not associated with PNI changes (28.2% versus 30.4%, <em>P</em> = 0.75).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that changes in PNI during neoadjuvant therapy may be associated with survival outcomes.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100223"},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival in patients with pancreatic cancer treated with second-line liposomal irinotecan plus 5-fluorouracil/leucovorin: observations from Korea, Italy, and Germany","authors":"S. Lonardi ,&nbsp;K. Potthoff ,&nbsp;L. Procaccio ,&nbsp;C. Yoo ,&nbsp;T. Macarulla ,&nbsp;F. Hedouin-Biville ,&nbsp;G.W. Prager","doi":"10.1016/j.esmogo.2025.100217","DOIUrl":"10.1016/j.esmogo.2025.100217","url":null,"abstract":"<div><div>Pancreatic cancer (PAC) is an aggressive disease with poor clinical outcomes. Liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) is the only approved therapy for metastatic PAC following gemcitabine-based therapy, based on the survival benefit demonstrated in the phase III NAPOLI-1 trial. Factors associated with long-term survival in this trial included age ≤65 years, Karnofsky performance status (KPS) ≥90, neutrophil-to-lymphocyte (N/L) ratio ≤5, carbohydrate antigen (CA) 19-9 &lt;59-times the upper limit of normal (ULN), and no liver metastases. Using real-world data from studies conducted in Korea, Italy, and Germany, this review aims to assess the suitability of prognostic factors identified in the NAPOLI-1 trial nomogram. In these real-world studies, a high CA19-9 level and a low N/L ratio were associated with long-term survival in patients treated with nal-IRI+5-FU/LV. The impact of albumin levels, body mass index (BMI), liver metastasis, and KPS on survival identified from the NAPOLI-1 trial was confirmed in some real-world analyses but not consistently. Factors such as patient age and number of previous lines of treatment that were not identified in the NAPOLI-1 nomogram may be associated with long-term survival with nal-IRI+5-FU/LV in the real-world. In conclusion, this review has shown that while prognostic factors are useful for patient stratification, their predictive value on the efficacy of nal-IRI+5-FU/LV is low, thus this treatment may also result in long-term survival in patients with apparently unfavorable characteristics.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy","authors":"M. Sugimori ,&nbsp;A. Hirotani ,&nbsp;H. Yamazaki ,&nbsp;M. Oshi ,&nbsp;K. Kawashima ,&nbsp;H. Tsuchiya ,&nbsp;Y. Kanemaru ,&nbsp;Y. Suzuki ,&nbsp;S. Onodera ,&nbsp;H. Miwa ,&nbsp;A. Nozaki ,&nbsp;K. Sugimori ,&nbsp;C. Kunisaki ,&nbsp;M. Kudo ,&nbsp;M. Morimoto ,&nbsp;S. Maeda","doi":"10.1016/j.esmogo.2025.100221","DOIUrl":"10.1016/j.esmogo.2025.100221","url":null,"abstract":"<div><h3>Background</h3><div>Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) therapies are widely used to treat advanced pancreatic ductal adenocarcinoma (PDAC). This study aimed to identify the prognostic factors associated with these regimens, focusing on key genomic alterations in the ‘Big Four’ genes (<em>KRAS, TP53, CDKN2A,</em> and <em>SMAD4</em>).</div></div><div><h3>Materials and methods</h3><div>This retrospective observational study analysed real-world data from 5205 PDAC patients registered in the national database, Center for Cancer Genomics and Advanced Therapeutics (C-CAT), who underwent comprehensive genomic profiling between June 2019 and December 2023 in Japan. Clinical characteristics and genomic alterations were analysed. Time to progression (TTP) was compared between patients treated with GnP or FFX as first-line therapy. Gene alterations were classified as truncating or missense mutations to assess prognostic relevance.</div></div><div><h3>Results</h3><div>GnP was more frequently selected than FFX as first-line treatment (2315 versus 1181). FFX was more commonly used in younger, male patients without prior adjuvant therapy. After matching for age, sex, and adjuvant history, GnP demonstrated superior TTP compared with FFX (median TTP: 6.0 versus 5.5 months, <em>P</em> = 0.019). In the GnP group, <em>TP53</em> alterations were associated with significantly shorter TTP compared with wild-type <em>TP53</em> (median TTP: 5.8 versus 7.0 months; <em>P</em> &lt; 0.0001). Furthermore, truncating <em>TP53</em> mutations were linked to shorter TTP than missense mutations (median TTP: 5.3 versus 5.9 months; <em>P</em> = 0.021).</div></div><div><h3>Conclusions</h3><div>In Japanese real-world data, GnP showed superior TTP compared with FFX for advanced PDAC. <em>TP53</em> status may serve as a prognostic biomarker in patients receiving GnP therapy.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100221"},"PeriodicalIF":0.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144813910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controversies in upper GI oncology: definition and management of oligometastatic gastroesophageal adenocarcinoma","authors":"A. Petrillo ,&nbsp;G. Piessen ,&nbsp;H.W.M. van Laarhoven","doi":"10.1016/j.esmogo.2025.100228","DOIUrl":"10.1016/j.esmogo.2025.100228","url":null,"abstract":"","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144813911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility and sexuality in early-onset colorectal cancer patients: a monocentric survey","authors":"A. Spring ,&nbsp;M.A. Calegari ,&nbsp;G. Valente ,&nbsp;G. Caira ,&nbsp;D. Barone ,&nbsp;F. Schietroma ,&nbsp;L. Chiofalo ,&nbsp;V. Beccia ,&nbsp;G. Trovato ,&nbsp;M. Chiaravalli ,&nbsp;M. Bensi ,&nbsp;M. Basso ,&nbsp;C. Pozzo ,&nbsp;G. Tortora ,&nbsp;L. Salvatore","doi":"10.1016/j.esmogo.2025.100213","DOIUrl":"10.1016/j.esmogo.2025.100213","url":null,"abstract":"<div><h3>Background</h3><div>Evidence concerning the impact of chemotherapy on sexual health and fertility in early-onset colorectal cancer (EO-CRC) patients is scarce.</div></div><div><h3>Patients and methods</h3><div>We aimed to assess through an anonymous online survey the effect of chemotherapy on sexual quality of life and fertility preservation management in patients with stage II-IV EO-CRC treated at our center. Sexual health was evaluated with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22) questionnaire. Fertility issues were assessed through a structured survey form.</div></div><div><h3>Results</h3><div>From 2010 to 2022, 139 out of 6444 patients were diagnosed with EO-CRC at our center. A total of 84 patients (60.4%) completed the survey, while 55 (39.6%) did not participate; 50 (59.5%) were women and 42 (50%) had stage II-III disease. Only 11.9% (8/67) of patients reported having discussed sexual issues with their oncologist, while 45% (18/40) received specific counseling about fertility preservation, with no statistically significant differences between sexes. Libido decrease and sexual pain were reported more often by women compared with men in each setting; the difference was statistically significant (<em>P</em> &lt; 0.05). A statistically significant correlation between age ≥45 years and persistent amenorrhea after adjuvant chemotherapy was reported (<em>P</em> &lt; 0.05). Three women and three men underwent ovarian tissue or sperm cryopreservation, respectively.</div></div><div><h3>Conclusions</h3><div>Clinicians tend to discuss fertility issues more often than sexual health with patients, regardless of sex. Women seem to experience more libido decrease and sexual pain compared with men, and their risk of persistent amenorrhea increases with age. Both fertility and sexuality counseling should be improved in EO-CRC management.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review","authors":"M. Fassan ,&nbsp;I. Chau ,&nbsp;H. Dasghaib ,&nbsp;J. Hill ,&nbsp;R. Pophale ,&nbsp;K. Shitara","doi":"10.1016/j.esmogo.2025.100210","DOIUrl":"10.1016/j.esmogo.2025.100210","url":null,"abstract":"<div><div>Claudin 18 isoform 2 (CLDN18.2) is a tight junction protein expressed in normal gastric tissue and retained in gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The phase III trials SPOTLIGHT and GLOW demonstrated improved survival following the addition of the CLDN18.2-targeted antibody zolbetuximab to chemotherapy. In this systematic literature review, we summarize existing evidence for the prognostic role of CLDN18.2 and association of CLDN18.2 with patient demographic and clinicopathological characteristics in patients with advanced G/GEJ adenocarcinoma. MEDLINE, Embase, clinical trials databases, and congress abstracts were searched for interventional and noninterventional studies that evaluated CLDN18.2 for patient/disease characteristics, survival, or expression of programmed death-ligand 1 as primary outcomes. Of 742 records identified, 18 publications (17 studies) were included. CLDN18.2 expression was not consistently associated with specific patient/disease characteristics in most studies; two studies reported an association of CLDN18.2 expression with Lauren classification but differed on its association with diffuse or intestinal histology. Most studies reported that CLDN18.2 expression was not a statistically significant prognostic factor; among those that reported CLDN18.2 as a prognostic factor, studies differed regarding the association of CLDN18.2 with worsened or improved prognosis. One study reported an association of CLDN18.2 expression with programmed death-ligand 1 expression. The use of different antibodies and definitions of CLDN18.2 positivity in patients with advanced G/GEJ adenocarcinoma poses a challenge for drawing definitive conclusions on the prognostic value of CLDN18.2 and association of CLDN18.2 with patient/disease characteristics. Additional research using a standardized approach to assess CLDN18.2 expression is needed.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100210"},"PeriodicalIF":0.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}